Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/USP33_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/USP33_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/USP33_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/USP33_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/USP33_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/USP33_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/USP33_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/USP33_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/USP33_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070981 | Oral cavity | OSCC | centrosome cycle | 66/7305 | 130/18723 | 4.17e-03 | 1.70e-02 | 66 |
GO:00706462 | Oral cavity | OSCC | protein modification by small protein removal | 77/7305 | 157/18723 | 6.55e-03 | 2.43e-02 | 77 |
GO:00310232 | Oral cavity | OSCC | microtubule organizing center organization | 70/7305 | 143/18723 | 9.71e-03 | 3.44e-02 | 70 |
GO:006156410 | Oral cavity | OSCC | axon development | 207/7305 | 467/18723 | 1.01e-02 | 3.51e-02 | 207 |
GO:003164726 | Oral cavity | EOLP | regulation of protein stability | 75/2218 | 298/18723 | 1.22e-10 | 1.35e-08 | 75 |
GO:001050622 | Oral cavity | EOLP | regulation of autophagy | 74/2218 | 317/18723 | 5.84e-09 | 3.07e-07 | 74 |
GO:005082126 | Oral cavity | EOLP | protein stabilization | 51/2218 | 191/18723 | 1.37e-08 | 6.40e-07 | 51 |
GO:005109824 | Oral cavity | EOLP | regulation of binding | 79/2218 | 363/18723 | 4.86e-08 | 1.81e-06 | 79 |
GO:005109924 | Oral cavity | EOLP | positive regulation of binding | 42/2218 | 173/18723 | 3.81e-06 | 8.06e-05 | 42 |
GO:004339323 | Oral cavity | EOLP | regulation of protein binding | 45/2218 | 196/18723 | 8.47e-06 | 1.61e-04 | 45 |
GO:000926721 | Oral cavity | EOLP | cellular response to starvation | 37/2218 | 156/18723 | 2.44e-05 | 3.62e-04 | 37 |
GO:007149625 | Oral cavity | EOLP | cellular response to external stimulus | 63/2218 | 320/18723 | 3.18e-05 | 4.49e-04 | 63 |
GO:003166823 | Oral cavity | EOLP | cellular response to extracellular stimulus | 51/2218 | 246/18723 | 4.36e-05 | 5.88e-04 | 51 |
GO:003209223 | Oral cavity | EOLP | positive regulation of protein binding | 23/2218 | 85/18723 | 9.95e-05 | 1.14e-03 | 23 |
GO:004259422 | Oral cavity | EOLP | response to starvation | 42/2218 | 197/18723 | 1.03e-04 | 1.17e-03 | 42 |
GO:003166923 | Oral cavity | EOLP | cellular response to nutrient levels | 44/2218 | 215/18723 | 1.92e-04 | 1.96e-03 | 44 |
GO:003166725 | Oral cavity | EOLP | response to nutrient levels | 82/2218 | 474/18723 | 2.59e-04 | 2.52e-03 | 82 |
GO:007064611 | Oral cavity | EOLP | protein modification by small protein removal | 33/2218 | 157/18723 | 7.04e-04 | 5.78e-03 | 33 |
GO:00165792 | Oral cavity | EOLP | protein deubiquitination | 28/2218 | 139/18723 | 3.29e-03 | 1.90e-02 | 28 |
GO:00705362 | Oral cavity | EOLP | protein K63-linked deubiquitination | 10/2218 | 35/18723 | 5.99e-03 | 3.00e-02 | 10 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
USP33 | SNV | Missense_Mutation | | c.1236C>G | p.Ile412Met | p.I412M | Q8TEY7 | protein_coding | tolerated(0.23) | benign(0.015) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
USP33 | SNV | Missense_Mutation | novel | c.1978C>A | p.Leu660Met | p.L660M | Q8TEY7 | protein_coding | tolerated(0.07) | possibly_damaging(0.688) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
USP33 | SNV | Missense_Mutation | | c.1728N>G | p.Phe576Leu | p.F576L | Q8TEY7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A085-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
USP33 | SNV | Missense_Mutation | | c.318C>A | p.Asn106Lys | p.N106K | Q8TEY7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR |
USP33 | SNV | Missense_Mutation | novel | c.61A>C | p.Ser21Arg | p.S21R | Q8TEY7 | protein_coding | deleterious_low_confidence(0.05) | benign(0.076) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP33 | SNV | Missense_Mutation | | c.1031N>T | p.Asn344Ile | p.N344I | Q8TEY7 | protein_coding | tolerated(0.2) | benign(0.102) | TCGA-E2-A150-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
USP33 | insertion | Nonsense_Mutation | novel | c.2806_2807insCAGATCCATAGTATCCTTTGTAGTGTTGTAAAT | p.Glu936delinsAlaAspProTerTyrProLeuTerCysCysLysTer | p.E936delinsADP*YPL*CCK* | Q8TEY7 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
USP33 | SNV | Missense_Mutation | novel | c.2081T>C | p.Val694Ala | p.V694A | Q8TEY7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
USP33 | SNV | Missense_Mutation | | c.968N>T | p.Ser323Phe | p.S323F | Q8TEY7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
USP33 | SNV | Missense_Mutation | | c.968N>T | p.Ser323Phe | p.S323F | Q8TEY7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |